HBV

AusperBio Welcomes Dr. Will Wei as Head of CMC

Retrieved on: 
Wednesday, January 3, 2024
Organic chemistry, Lead, Drug development, HBV, Roche, CMC, Health, SAN, Therapy, Hepatitis, GSK, University, CHB, SVP, Scripps Research, Head

"We are excited to welcome Dr. Wei to AusperBio's leadership team at this pivotal time for the company," said Dr. Guofeng Cheng, chief executive officer.

Key Points: 
  • "We are excited to welcome Dr. Wei to AusperBio's leadership team at this pivotal time for the company," said Dr. Guofeng Cheng, chief executive officer.
  • "Will's depth and breadth of experience in end-to-end CMC operations, strategic insight will be instrumental in executing our plans, propelling our pipeline, and navigating the dynamic landscape of drug development."
  • Bringing over two decades of outstanding leadership in the biotech and pharmaceutical industry, Dr. Wei has excelled across critical domains in drug development.
  • Dr. Wei earned his Ph.D. in the Department of Organic Chemistry at the University of Lausanne in Switzerland and completed his postdoctoral training at The Scripps Research Institute.

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

Retrieved on: 
Wednesday, January 3, 2024
SPL, Hepatitis B virus, Partnership, Hepatocellular carcinoma, Immune system, Research, TCR, Lion, HBV, Cell engineering, MBA, Laboratory, Viral, Cancer, Patient, Safety, Therapy, Vaccine

This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.

Key Points: 
  • This partnership will enhance MaxCyte's presence in Asia, with anticipated expansion into the US and European markets.
  • Under the terms of the agreement, Lion TCR obtains worldwide non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • “We are thrilled to partner with Lion TCR to support the development of their TCR-T cell therapies for hepatocellular carcinoma and life-threatening viral infections,” said Maher Masoud, President and CEO of MaxCyte.
  • Lion TCR is MaxCyte’s 24th strategic partnership overall, each of which generates pre-commercial milestone revenue and the vast majority of which include sales-based payments.

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

Retrieved on: 
Thursday, December 7, 2023
Liver, AASLD, Multiple, NASH, SHBG, HBV, MBA, SAN, Therapy, Thyroid, THR, Doctor of Philosophy, HBeAg, CccDNA, Safety, Patient, Pharmacology, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, delivered oral presentations of clinical data for its capsid assembly modulator-empty (CAM-E), ALG-000184, and its thyroid hormone receptor-beta (THR-β) drug candidate, ALG-055009, at the Hep-DART 2023 meeting, held in Cabo San Lucas, Mexico, from December 3 – 7, 2023.
  • The presentations can be found on the “Scientific Presentations & Conferences” section of the Aligos website ( www.aligos.com ).
  • “We’re greatly encouraged by the substantial and consistent reductions in HBV viral markers observed during prolonged dosing of ALG-000184 and are grateful for the opportunity to share these results with the scientific community at the Hep-DART 2023 meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • As presented at AASLD, ALG-055009 appears to have best-in-class potential.

Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics

Retrieved on: 
Tuesday, November 14, 2023
Yale University, Lung, Canadian Tire money, Brain, Research, AstraZeneca, Therapy, Joint venture, IND, Non-small-cell lung cancer, Disease, Clinical trial, Osimertinib, Patient, HBV, International joint venture, Immunotherapy, Animal, Neoplasm, TKI, Lung cancer, MD, Person, Infection, NSCLC, Human, SITC, BioRxiv, Malaria, Society, EGFR, Brown University Graduate School, Fibrosis, Pharmaceutical industry, Vaccine, CHI3L1, Cancer, Ocean, Virus

These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.

Key Points: 
  • These new data demonstrate complete and highly reproducible tumor clearance, and protection upon tumor rechallenge, months after animals cleared their initial tumors.
  • VRON-0300 IND-enabling activities are underway, with the goal of filing its first IND within the next 9 months.
  • Virion Therapeutics is developing novel immunotherapies that utilize proprietary genetically encoded checkpoint modifiers (CPMs) to enhance and broaden CD8+ T cells responses.
  • Preclinical studies using CPMs have shown consistent and extraordinary immune responses and clinical activity in different diseases.

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

Retrieved on: 
Friday, November 10, 2023
Hepatology, VBR, Interferon, Viral, SAN, Hepatitis B virus, AASLD, Liver, Biotechnology, Patient, HBV, ISG, Assembly, HCV, Doctor of Philosophy, Poster, Pharmaceutical industry, Vaccine, Boston

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced new data from its virology portfolio featured in two presentations at the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, taking place November 10-14, 2023, in Boston.
  • “Additionally, the Phase 2 data reported for vebicorvir in combination with Nrtl and Arbutus Biopharma’s AB-729 provide further insights that may inform future studies for the HBV and liver disease scientific community."
  • In addition, oral administration to preclinical species resulted in ISG induction in the liver and peripheral blood mononuclear cells (PBMCs).
  • Assembly Bio intends to make the presentations available on the “Events & Presentations” page in the “Investors” section of its website at www.assemblybio.com.

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Retrieved on: 
Thursday, November 9, 2023
Group 3, Hepatology, Safety, Immune system, Thyroiditis, RNA interference, AASLD, Risk, MVA, NUC, Patient, HBV, Clinical trial, Non-cirrhotic portal fibrosis, Liver, SOC, Autoimmune thyroiditis, CHB, Cancer, Nivolumab, Hepatitis, Group 2, Autoimmunity, Thyroid disease, Șaeș, Vaccine, Pharmaceutical industry, HBsAg

Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.

Key Points: 
  • Alongside this, a late-breaking poster presentation with interim data from patients with chronic hepatitis B (CHB) from the Phase 2a AB-729-202 trial combining Arbutus Biopharma Corporation’s (NASDAQ: ABUS) RNAi therapeutic candidate, imdusiran (AB-729), with Barinthus Bio’s T cell stimulating immunotherapeutic candidate, VTP-300, and SoC NUC therapy.
  • Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production was enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Virology, Immune system, University of Hong Kong, AASLD, Patient, HBV, Clinical trial, Division, Non-cirrhotic portal fibrosis, Liver, University, Cancer, Autoimmunity, CFBV, Vaccine, Pharmaceutical industry, HBsAg, Gastroenterology

WARMINSTER, Pa. and OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a cure for people with chronic hepatitis B virus (cHBV) infection, and Barinthus Biotherapeutics plc (Nasdaq: BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023. The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.

Key Points: 
  • The poster contains preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran (AB-729), with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy.
  • Preliminary immunology data suggests HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.
  • The preliminary safety data from this trial demonstrate that imdusiran and VTP-300 were both safe and well-tolerated.
  • Dr. Karen Sims, Chief Medical Officer of Arbutus Biopharma, commented, “Imdusiran consistently delivers compelling efficacy and safety data in multiple Phase 2a populations and combinations.

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 9, 2023
Hepatology, Research, Immune system, Depreciation, HBV, Hepatitis B, Arbutus, Vaccine, Liver, Infection, Healing, Cancer, Autoimmunity, Pharmaceutical industry, Vaccitech

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.

Key Points: 
  • OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.
  • “The third quarter of 2023 was a period of solid progress for the Company.
  • We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio.
  • Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023.

Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B

Retrieved on: 
Wednesday, December 6, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Other Health, Biotechnology, General Health, Health, Science, Other Science, DNA methylation, Chromosome, DNA, Therapy, Hepatitis B virus, Liver, Tune, Mouse, HBV, Patient, TEMPO, Chimera, Hepatocyte, PCSK9, Genome, FRG, Vaccine, Dietary supplement, Medical device, CccDNA

Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.

Key Points: 
  • Leading epigenome editing company Tune Therapeutics presented data in support of its chronic Hepatitis B Virus (HBV) program, demonstrating the ability to durably silence essential mechanisms of viral replication and persistence across a range of model systems.
  • Importantly, the TEMPO platform does this via epigenetic processes, and without cutting, damaging, or altering genomic DNA sequences in any way.
  • “Through the richness of these data sets, we found multiple repression candidates that worked well in both contexts.
  • As such, they represent the gold standard for assessing the dose and efficacy for liver-directed therapeutics ahead of human clinical trials.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Monday, November 20, 2023
Health, Infectious Diseases, COVID-19, Clinical Trials, Research, Science, Pharmaceutical, Sale, Heart, Southampton General Hospital, Pediatrics, Patient, Conference, Doctor of Philosophy, Viral, Webcast, Safety, RSV, Human, Respiratory system, MBBS, Federal, Chronic obstructive pulmonary disease, Texas A&M University, O'Driscoll (surname), Dean (education), Respiratory Medicine, Pharmacokinetics, University, FRCP, Fast Track, Asthma, Medication, Infection, FERS, Urinary tract infection, Virology, Ageing, Upper respiratory tract infection, Viral load, Clinical trial, Tax, HBV, FDA, Vaccine, Faculty, OMERS, HCV, State Administrative Expenses, Pharmaceutical industry, Life insurance, Cryptocurrency, Pfizer, Cantab, FIDSA, FAAP, Medicine, MD

(NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.

Key Points: 
  • (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today reported financial results for its fiscal fourth quarter and year ended September 30, 2023.
  • For the twelve months ended September 30, 2023, total revenue was $79.2 million compared to $86.2 million for the same period in 2022.
  • The decrease in the quarter and in year-over-year revenue is due to a decline in AbbVie’s sales of MAVYRET®/MAVIRET®.
  • Non-cash interest expense was $3.2 million for the three months ended September 30, 2023 and $5.1 million for the twelve months ended September 30, 2023.